Tech Company Financing Transactions

Inotek Pharmaceuticals Funding Round

Devon Park Bioventures, Care Capital and Edbi joined a $18 million Series D funding round for Inotek Pharmaceuticals. The round was recorded on 6/11/2010.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

1202 Water St.
Walnut Creek, CA 94597
USA

Phone

781-457-1446

Website

www.inotekpharma.com

Email Address

[email protected]

Overview

Inotek Pharmaceuticals is a clinical-stage, publicly traded, biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat glaucoma and other serious diseases of the eye.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

David Southwell

        

Chief Medical Officer

Rudolf Baumgartner

        

Chief Scientific Officer

William McVicar

        

VP - Finance

Dale Ritter

        

Browse more venture capital transactions:

Prev: 6/11/2010: BioScale venture capital transaction
Next: 6/11/2010: Precision Therapeutics venture capital transaction

Share this article

News on VC Transactions

We do our best to report on every notable VC transaction. VC investment data records reported here come from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary